AboutOpen https://journals.aboutscience.eu/index.php/aboutopen <p>This open access journal publishes peer reviewed articles on clinical studies, real world evidence data, reviews, point of views, case series, and single clinical cases. The journal aim and scope encompasses clinical medicine, pharmacy, healthcare technology and other healthcare related disciplines with a focus on innovation in healthcare and policy. Articles may be in English, French, Italian and Spanish</p> en-US <p>Authors contributing to&nbsp;<em>AboutOpen</em>&nbsp;agree to publish their articles under the <a href="https://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener">Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0)</a>, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.&nbsp;</p> lucia.steele@aboutscience.eu (Lucia Steele) production@aboutscience.eu (Silvia Minora) Mon, 02 Mar 2020 13:02:27 +0000 OJS http://blogs.law.harvard.edu/tech/rss 60 Kidney Diseases: Challenges and Opportunities of the Third Millenium https://journals.aboutscience.eu/index.php/aboutopen/article/view/2029 Antonio Bellasi, Biagio Di Iorio, Luca Di Lullo ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://journals.aboutscience.eu/index.php/aboutopen/article/view/2029 Mon, 09 Mar 2020 15:35:17 +0000 A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy https://journals.aboutscience.eu/index.php/aboutopen/article/view/2030 <p class="abstract"><strong>Introduction:</strong> Granulocyte-colony stimulating factors (G-CSFs) can significantly reduce the risk of febrile neutropenia (FN) among certain patients receiving chemotherapy. FN is associated with significant clinical and nonclinical complications. At present, the patent protection of pegfilgrastim (Neulasta®) has expired, and a biosimilar (Ziextenzo®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings).<br><strong>Methods and Results:</strong> The model time horizon extends to five years. The initial overall number of treatments with pegfilgrastim is estimated based on the number of pegfilgrastim packages (assuming a recommended dose of 6 mg is administered after each cytotoxic chemotherapy) and kept constant in time. The model assumes that, year by year, the number of treatments with the originator will partly switch to the biosimilar (according to an uptake rate assumed). The results show that the availability of the biosimilar would provide an €6.4 million cumulated savings to the NHS in the five years.<br><strong>Conclusions:</strong> According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €6.4 million for the Italian NHS.&nbsp;</p> <p class="abstract">(HTA &amp; Market Access)</p> Roberto Ravasio, Lorenzo Antonuzzo, Marco Danova, Paolo Pronzato ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://journals.aboutscience.eu/index.php/aboutopen/article/view/2030 Mon, 02 Mar 2020 00:00:00 +0000 Words for pharma: a quantitative and qualitative analysis on vision, mission and values of multinational pharma companies. https://journals.aboutscience.eu/index.php/aboutopen/article/view/2104 <p><strong>Introduction</strong>: Pharma companies deal with the same important challenges that humans face: to grow and stay healthy. The crucial role of pharma companies in preserving health would suggest that they might rank highly in the reputation indexes. However, this does not seem to be the case. Our aim was to collect, cluster and analyse the words used by pharma companies in their mission, vision and value statements as a base to identify areas of improvement in their corporate communication.</p> <p><strong>Methods</strong>: A total of 97 multinational pharma companies were selected based on their size and presence within major markets. Mission, vision and company values were captured from company websites and analysed. Word clouds were built to analyse the frequency of words in the statement. The influence of company size and location was also analysed.</p> <p><strong>Results</strong>: Most companies (90.7%) have a mission and 54.6% have a clearly stated vision statement, 71.4% mention values. “Life/lives” “patients”, “innovative”, “people/persons” are the most frequently used words. “Innovation” and “integrity” are by far the most common values, followed by “respect”, “ethics”, “responsibility” and “passion”. References to healthcare professionals, access to treatment and sustainability, open science, transparency and care for the environment are more scanty.</p> <p><strong>Conclusions</strong>: Most, but not all, pharma companies provide comprehensive statements focussing mostly on the innovation and its impact on patients. Topics such as role of health care professionals, economic sustainability and care for the environment are rarely listed. An in-depth analysis of their alignment with key needs and trending topics is warranted to further engage customers and build reputation and value.</p> Giulio Zuanetti, Francesca Giorgia Colombo, Carlotta Galeone ##submission.copyrightStatement## http://creativecommons.org/licenses/by-nc/4.0 https://journals.aboutscience.eu/index.php/aboutopen/article/view/2104 Thu, 30 Apr 2020 13:16:55 +0000